Pharmacological treatment directions of idiopathic pulmonary fibrosis current options and future directions

Abstract

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and ultimately fatal interstitial lung disease characterized by irreversible fibrosis of the lung parenchyma. It predominantly affects individuals over 50 years of age, especially males with a history of smoking, and presents with non-specific symptoms such as progressive exertional dyspnea and a persistent dry cough, often leading to delayed diagnosis. Pathophysiologically, IPF is driven by repetitive alveolar epithelial injury in genetically predisposed individuals, leading to dysregulated repair mechanisms, fibroblast activation, and excessive extracellular matrix deposition. Key molecular players include transforming growth factor-beta (TGF-β), telomere dysfunction, and aberrant epithelial-mesenchymal interactions. Current pharmacological management includes the antifibrotic agents pirfenidone and nintedanib, both of which have demonstrated efficacy in slowing the rate of forced vital capacity (FVC) decline and reducing mortality risk, though they do not reverse the disease.Supportive care—such as oxygen therapy, pulmonary rehabilitation, and palliative care plays a crucial role in symptom management and quality of life enhancement. Recent research has shifted from inflammation-based models to a fibrotic paradigm, with ongoing trials exploring novel therapeutic targets like autotaxin inhibitors, monoclonal antibodies, and regenerative medicine approaches. Future directions emphasize early diagnosis, personalized medicine, and improved trial designs to develop more effective and better-tolerated therapies.